Literature DB >> 4073865

Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare.

M H Cynamon.   

Abstract

The susceptibilities of 20 clinical isolates of Mycobacterium intracellulare to rifampin, MDL 473, and ansamycin were determined by broth and agar dilution methods. Ansamycin was more active than MDL 473, which in turn was usually more active than rifampin by either method. The MICs for 90% of the strains tested by agar dilution were 1, 2, and 4 micrograms of ansamycin, MDL 473, and rifampin per ml, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073865      PMCID: PMC180270          DOI: 10.1128/AAC.28.3.440

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Effect of temperature on the rate of the transparent to opaque colony type transition in Mycobacterium avium.

Authors:  C L Woodley; H L David
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Permeability barrier to rifampin in mycobacteria.

Authors:  J Hui; N Gordon; R Kajioka
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

Review 3.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

4.  Rifampin: in vitro effect on atypical mycobacteria.

Authors:  T K Rynearson; J S Shronts; E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1971-08

5.  Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifampicin.

Authors:  M D Yates; C H Collins
Journal:  J Antimicrob Chemother       Date:  1982-08       Impact factor: 5.790

6.  The pleiotropic effect of spontaneous single-step variant production in Mycobacterium intracellulare.

Authors:  R Kajioka; J Hui
Journal:  Scand J Respir Dis       Date:  1978-04

7.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.

Authors:  C L Woodley; J O Kilburn
Journal:  Am Rev Respir Dis       Date:  1982-09

9.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors:  N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases.

Authors:  D Y Rosenzweig
Journal:  Chest       Date:  1979-02       Impact factor: 9.410

View more
  25 in total

1.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Rifabutin and rifapentine compared with rifampin against Mycobacterium leprae in mice.

Authors:  S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

4.  In vivo activities of newer rifamycin analogs against Mycobacterium avium infection.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

5.  Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Authors:  A M Lenaerts; S E Chase; A J Chmielewski; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

7.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.

Authors:  S P Klemens; M A Grossi; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.